retatrutide peptide side effects (LY3437943) — Dosing, Effects, FDA Status & Research | PeptIQ Retatrutide Promises Big Weight Loss,

GLP-1 agonists have different safety constraints: absolute contraindication in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and caution in patients with diabetic retinopathy or severe gastrointestinal disease

In your pancreas, GIP strongly stimulates insulin secretion when blood glucose is elevated

When to worry: No bowel movement for 5+ days despite interventions

In Phase 3 trials, nausea affected up to 42.4% of people, diarrhoea up to 34.1%, constipation up to 26.1%, and vomiting up to 25.3%, depending on the dose

These medications are covered based on medical necessity and require prior authorization from the members physician